<SEC-DOCUMENT>0001213900-25-073993.txt : 20250811
<SEC-HEADER>0001213900-25-073993.hdr.sgml : 20250811
<ACCEPTANCE-DATETIME>20250811090002
ACCESSION NUMBER:		0001213900-25-073993
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20250811
FILED AS OF DATE:		20250811
DATE AS OF CHANGE:		20250811

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Tiziana Life Sciences Ltd
		CENTRAL INDEX KEY:			0001723069
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				000000000
		STATE OF INCORPORATION:			D0
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38723
		FILM NUMBER:		251200404

	BUSINESS ADDRESS:	
		STREET 1:		3RD FLOOR, 11-12 ST. JAMES'S SQUARE
		CITY:			LONDON, ENGLAND
		STATE:			X0
		ZIP:			SW1Y 4LB
		BUSINESS PHONE:		0044(0) 207-495-2379

	MAIL ADDRESS:	
		STREET 1:		3RD FLOOR, 11-12 ST. JAMES'S SQUARE
		CITY:			LONDON, ENGLAND
		STATE:			X0
		ZIP:			SW1Y 4LB

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Tiziana Life Sciences plc
		DATE OF NAME CHANGE:	20171116
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>ea0252614-6k_tiziana.htm
<DESCRIPTION>REPORT OF FOREIGN PRIVATE ISSUER
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B></B></P>

<!-- Field: Rule-Page --><DIV STYLE="width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>UNITED STATES</B></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Washington, D.C. 20549</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Rule-Page --><DIV STYLE="margin-left: auto; margin-right: auto; width: 50%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>FORM&nbsp;6-K</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Rule-Page --><DIV STYLE="margin-left: auto; margin-right: auto; width: 50%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>REPORT OF FOREIGN PRIVATE ISSUER</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PURSUANT TO RULE 13a-16 OR 15d-16</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>UNDER THE SECURITIES EXCHANGE ACT OF 1934</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>August 2025</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Rule-Page --><DIV STYLE="margin-left: auto; margin-right: auto; width: 50%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Commission File Number:</B>&nbsp; <B>001-38723</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Rule-Page --><DIV STYLE="margin-left: auto; margin-right: auto; width: 50%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Tiziana Life Sciences LTD</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Exact Name of Registrant as Specified in Its Charter)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Rule-Page --><DIV STYLE="margin-left: auto; margin-right: auto; width: 50%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="background-color: white"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="background-color: white"><B>9<SUP>th</SUP>&nbsp;Floor</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="background-color: white"><B>107 Cheapside</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="background-color: white"><B>London
</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="background-color: white"><B>EC2V 6DN</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Address of registrant&rsquo;s principal executive
office)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<!-- Field: Rule-Page --><DIV STYLE="margin-left: auto; margin-right: auto; width: 50%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Indicate by check mark whether the registrant files or will file annual
reports under cover of Form&nbsp;20-F or Form&nbsp;40-F.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Form&nbsp;20-F
&#9746;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;Form&nbsp;40-F &#9744;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Rule-Page --><DIV STYLE="width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>INFORMATION CONTAINED IN THIS REPORT ON FORM&nbsp;6-K</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">On August 11, 2025, Tiziana Life Sciences LTD (the &ldquo;<U>Company</U>&rdquo;)
issued this 6K announcing, that the U.S. Food &amp; Drug Administration (FDA) have approved the IND for its Phase 2a clinical trial of
intranasal foralumab in patients with Multiple System Atrophy (MSA). Multiple System Atrophy is an unmet medical need as there are currently
no FDA approved therapies to treat this life limiting, orphan designated disease.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">The Announcement is furnished herewith as Exhibit
99.1 to this Report on Form&nbsp;6-K. The information in the attached Exhibits 99.1 is being furnished and shall not be deemed &ldquo;filed&rdquo;
for the purposes of Section&nbsp;18 of the Securities Exchange Act of 1934, or otherwise subject to the liabilities of that Section, nor
shall it be deemed incorporated by reference in any filing made by the Company under the Securities Act of 1933, as amended, or the Securities
Exchange Act of 1934, except as otherwise set forth herein or as shall be expressly set forth by specific reference in such a filing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SIGNATURES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="3"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>TIZIANA LIFE SCIENCES LTD</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%">&nbsp;</TD>
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="width: 32%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Date: August 11, 2025</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">By:</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">/s/ Keeren Shah</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Name:</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;Keeren Shah</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Title:</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Chief Financial Officer</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<!-- Field: Page; Sequence: 3; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>EXHIBIT&nbsp;INDEX</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 9%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit&nbsp;No.</B></FONT></TD>
    <TD STYLE="width: 1%; text-align: center">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 90%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Description</B></FONT></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">99.1</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="ea025261401ex99-1_tiziana.htm">Tiziana Life Sciences LTD Press Release, dated August 11, 2025</A></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 4; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>ea025261401ex99-1_tiziana.htm
<DESCRIPTION>TIZIANA LIFE SCIENCES LTD PRESS RELEASE, DATED AUGUST 11, 2025
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 99.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B><IMG SRC="ex99-1_001.jpg" ALT=""></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>FDA Approves Tiziana Life Sciences Phase 2 IND
for Multiple System Atrophy</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">NEW YORK, August 11, 2025 &ndash; Tiziana Life Sciences, Ltd. (Nasdaq:
TLSA) (&ldquo;Tiziana&rdquo; or the &ldquo;Company&rdquo;), a biotechnology
company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3
monoclonal antibody, is pleased to announce that the U.S. Food &amp; Drug Administration (FDA) have approved the IND for its Phase 2a
clinical trial of intranasal foralumab in patients with Multiple System Atrophy (MSA). Multiple System Atrophy is an unmet medical need
as there are currently no FDA approved therapies to treat this life limiting, orphan designated disease.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Phase 2a study (ClinicalTrials.gov Identifier: NCT06868628)
is a six-month, open-label clinical trial designed to evaluate the effects of intranasal foralumab on microglial activation, clinical
outcomes, and safety in MSA patients. Foralumab, a fully human anti-CD3 monoclonal antibody targets T-cell mediated neuroinflammation
and is administered via nasal spray in eight 3-week dosing cycles.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Multiple System Atrophy is an orphan disease, with a mean
incidence in the US of 0.6:100,000 person-years, increasing with &ge;50 years of age to 3:100,000 person-years. Prevalence estimates
for MSA range from 1.9-4.9 per 100,000 worldwide, suggesting that environmental, genetic, and epigenetic influences contribute to
disease pathogenesis. MSA is a rapidly progressive neurodegenerative disorder affecting autonomic functions (such as blood pressure,
bladder control) and motor control, leading to severe disability and shortened life expectancy. Increasing evidence implicates
neuroinflammation and microglial activation as key drivers in MSA pathogenesis, contributing to neuronal degeneration. Disease
progression is assessed using the unified MSA rating scale (UMSARS), which rates activities of daily life, autonomic and motor
impairment, as well as overall disability. Disease prognosis is poor with a median survival of 6-9 years.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&ldquo;We are pleased that the FDA have approved the IND to treat MSA
patients with nasal foralumab,&rdquo; said Vikram&#8239;Khurana, MD, PhD, Tracy T. Batchelor Endowed Chair in Neurology, and Division
Chief of Movement Disorders and Director of the MSA Center of Excellence at Brigham and Women&rsquo;s Hospital and Principal Investigator
of the MSA trial. &ldquo;Neuroinflammation plays a significant role in MSA&rsquo;s rapid progression. Intranasal foralumab offers a novel
therapeutic pathway by targeting T-cell mediated immune activation in the brain. We aim to observe whether this therapy can meaningfully
impact microglial activity and important clinical outcomes over six months in patients with MSA.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Ivor Elrifi, Chief Executive Officer of Tiziana Life Sciences commented
on the rationale of foralumab for the treatment of MSA; &ldquo;Foralumab administered intranasally induces regulatory T cells and modulates
T-cell-driven inflammation. Its ability to reduce microglial activation presents a promising therapeutic strategy to slow neuronal damage
in neuroinflammatory and degenerative diseases such as Multiple Sclerosis, Alzheimer&rsquo;s Disease, ALS, and MSA. This novel, non-systemic
approach is designed to engage regulatory T cells, promoting immune tolerance while minimizing systemic immune suppression.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>About Foralumab</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Foralumab, a fully human anti-CD3 monoclonal antibody, is a biological
drug candidate that has been shown to stimulate T regulatory cells when dosed intranasally. At present, 10 patients with Non-Active Secondary
Progressive Multiple Sclerosis (na-SPMS) have been dosed in an open-label intermediate sized Expanded Access (EA) Program (NCT06802328)
with either an improvement or stability of disease seen within 6 months in all patients. In addition, intranasal foralumab is currently
being studied in a Phase 2a, randomized, double-blind, placebo-controlled, multicenter, dose-ranging trial in patients with non-active
secondary progressive multiple sclerosis (NCT06292923).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Foralumab is the only fully human anti-CD3 monoclonal antibody (mAb)
currently in clinical development. The non-active SPMS intranasal foralumab Phase 2 trial (NCT06292923) began screening patients in November
of 2023. Immunomodulation by intranasal foralumab represents a novel avenue for the treatment of neuroinflammatory and neurodegenerative
human diseases.<SUP>[1],[2]</SUP></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>About Tiziana Life Sciences</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Tiziana Life Sciences is a clinical-stage biopharmaceutical company
developing breakthrough therapies using transformational drug delivery technologies to enable alternative routes of immunotherapy. Tiziana&rsquo;s
innovative nasal approach has the potential to provide an improvement in efficacy as well as safety and tolerability compared to intravenous
(IV) delivery. Tiziana&rsquo;s lead candidate, intranasal foralumab, which is the only fully human anti-CD3 mAb currently in clinical
development, has demonstrated a favorable safety profile and clinical response in patients in studies to date. Tiziana&rsquo;s technology
for alternative routes of immunotherapy has been patented with several applications pending and is expected to allow for broad pipeline
applications.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">For more information about Tiziana Life Sciences and its innovative
pipeline of therapies, please visit www.tizianalifesciences.com.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">For further inquiries:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Tiziana Life Sciences Ltd</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Paul Spencer, Business Development, and Investor Relations<BR>
+44 (0) 207 495 2379<BR>
email:&nbsp;info@tizianalifesciences.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in; text-align: left"><SUP>[1]</SUP></TD><TD STYLE="text-align: justify">https://www.pnas.org/doi/10.1073/pnas.2220272120</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in; text-align: left"><SUP>[2]</SUP></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">https://www.pnas.org/doi/10.1073/pnas.2309221120</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>ex99-1_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex99-1_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1"  B )8# 2(  A$! Q$!_\0
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M?'[Q[K7CC[7?;WO;KPWIPCT'0+B6>;=/,E\UGJ.II+*\C3+?"<NYDW'\*O\
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MEJUTUCI=WXU\4:+X9M]1O$3S)+6QEUF]LTNIXXR'>* NZ*59@ PS^$'[>/\
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M&B6<>G/I025+9;Z\#;D%%WY+T5M@Y5OKLUN^NCL?H!^R-\&-6_9T_9<_9\^
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M_AW4].BU_3UBN+B);/5DN[98YYD$865PW]L<))AB))),49)/))*#))[DT44
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7:EH^E6=Y'8:IJ-FDPM[ZYCE*** /_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
